# Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)

> **NCT02142205** · PHASE4 · COMPLETED · sponsor: **Biogen** · enrollment: 100 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis

## Interventions

- **BIOLOGICAL:** BG00002

## Key facts

- **NCT ID:** NCT02142205
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-05
- **Primary completion:** 2013-12
- **Final completion:** 2013-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2014-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02142205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02142205, "Safety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02142205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*